LLYEli Lilly and CompanyNot started yet
A Study of Olomorasib (LY3537982) in Participants With Advanced Colorectal Cancer and a KRAS G12C Mutation
Colorectal Neoplasms
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 50 (planned)
- Started
- Oct 2026
- Main results expected
- Nov 2028
- Fully finished
- Nov 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Measured over: Baseline until Disease Progression (PD) or Participant Stops Study (Estimated up to 15 Months)
Progression-Free Survival (PFS) Per RECIST v1.1
Measured over: Baseline to the Date of First Documented Progression of Disease or Participant Stops Study (Estimated up to 21 Months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07814417 · record last updated 2026-10-15 · checked 2026-11-09 15:42 UTC